Money Control Place
  • Politics
  • Business
  • Stocks
  • Investing
  • Politics
  • Business
  • Stocks
  • Investing

Money Control Place

Investing

BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer

by August 29, 2023
August 29, 2023
BriaCell Awarded National Cancer Institute Grant to Advance its Bria-OTS Immunotherapy for Cancer
NCI award (non-dilutive grant) further validates novel personalized off-the-shelf immunotherapy approach; and may facilitate future non-dilutive funding opportunities

 briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (‘BriaCell’ or the ‘Company’), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), the United States federal government’s principal agency for cancer research and training, has awarded the Company a research grant to advance its platform of personalized off-the-shelf immunotherapies for cancer.

The grant award of non-dilutive funds is titled ‘An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors’. The Company intends to use the funds for the development of Bria-OTS, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma.

‘There is an urgent need for breakthrough cancer treatments that would improve both survival and quality of life of cancer patients, especially in those with advanced disease. Our clinical findings to date show promising top-line survival and quality of life outcomes in patients treated with our personalized immunotherapy,’ stated Dr. William V. Williams, BriaCell’s President and CEO. ‘We would like to thank NCI for its generous support, recognizing the urgency for this unmet medical need, and considering our novel technology, among numerous other applicants, as a treatment that could potentially revolutionize cancer care. The NCI award further validates our approach and may facilitate future non-dilutive funding opportunities.’

‘Historically, the manufacturing and administration of personalized cancer treatments have been very time-consuming, complicated, and costly,’ stated Dr. Miguel Lopez-Lago, BriaCell’s Chief Scientific Officer. ‘Our cutting-edge off-the-shelf personalized immunotherapies have the potential to address all these issues and may represent a major advancement in cancer care.’

About briacell therapeutics corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/ .

Safe Harbor

This press release contains ‘forward-looking statements’ that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as ‘anticipate,’ ‘believe,’ ‘contemplate,’ ‘could,’ ‘estimate,’ ‘expect,’ ‘intend,’ ‘seek,’ ‘may,’ ‘might,’ ‘plan,’ ‘potential,’ ‘predict,’ ‘project,’ ‘target,’ ‘aim,’ ‘should,’ ‘will,’ ‘would,’ or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including in relation to (i) intends to use the funds for the development of Bria-OTS; (ii) the results of any research and development of Bria-OTS; (iii) ability to obtain future non-dilutive funding; and (iv) the ability to address issues relating to manufacturing and administration of personalized cancer treatments, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading ‘Risks and Uncertainties’ in the Company’s most recent Management’s Discussion and Analysis, under the heading ‘Risk Factors’ in the Company’s most recent Annual Information Form, and under ‘Risks and Uncertainties’ in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and briacell therapeutics corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

Investor Relations Contact:
CORE IR
investors@briacell.com

News Provided by GlobeNewswire via QuoteMedia

This post appeared first on investingnews.com
0
FacebookTwitterGoogle +Pinterest
previous post
Romios Gold Resources
next post
6 Lithium-ion Battery Types (Updated 2023)

Related Posts

Admission to Trading on the Ghana Stock Exchange

May 15, 2024

BHP to Spend up to A$40M to Explore...

March 10, 2025

When and How to Take a Long Position...

September 15, 2023

S&P Global: Mining Sector Sees Mixed Q1, Next...

May 18, 2025

How to Invest in Pharmaceutical Companies (Updated 2023)

July 28, 2023

Jindalee on Path to Emerge as Major US...

May 28, 2024

McEwen, Meding: Buying Gold Juniors Now, Watching Copper...

February 16, 2024

Black Mountain Drilling Results: First Significant Lithium Intersections...

February 8, 2024

Pampa Metals Intersects 304m at 1.07% CuEq* incl....

March 17, 2024

Stem Cell Stocks: 10 Biggest NASDAQ Companies in...

February 26, 2025

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest

    • The Best Five Sectors, #26

    • Top 5 Junior Gold Mining Stocks on the TSXV in 2025

    • Stallion Uranium Enters into Technology Data Acquisition Agreement

    • Kobo Resources Launches Limited Edition Jersey to Support Village Communities Through Kobo Cup CSR Initiative

    • Australian Mines Enters Earn-in Deal with Cabral for Boa Vista Gold Project

    • Trump’s Big Beautiful Bill to Rewrite America’s Energy, Mining and Tech Future

    Categories

    • Business (1,280)
    • Investing (2,648)
    • Politics (3,699)
    • Stocks (1,704)
    • Uncategorized (20)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: MoneyControlPlace.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 moneycontrolplace.com | All Rights Reserved